Radiotracers for fungal infection imaging

Medical Mycology

Volumn 49, Issue SUPPL. 1, 2011, Pages

  Lupetti, Antonella ^a   De Boer, Mark G J ^b   Erba, Paola ^a   Campa, Mario ^a   Nibbering, Peter H ^b  

^a UNIVERSITY OF PISA   (Italy)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

99m Tc antimicrobial peptides; 99m Tc fl uconazole; Aspergillus fumigatus; Candida albicans; fungal infection imaging

Indexed keywords

CHITINASE I 123; FLUCONAZOLE; FLUCONAZOLE F 18; FLUCONAZOLE TC 99M; HLF 111 TC 99M; HYNIC CHITIN BINDING PROTEIN 21 TC 99M; IMMUNOGLOBULIN G TC 99M; LACTOFERRIN; POLYPEPTIDE ANTIBIOTIC AGENT; RADIOPHARMACEUTICAL AGENT; TECHNETIUM 99M; TRACER; UBI 2941 TC 99M; UNCLASSIFIED DRUG;

ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; CANDIDA ALBICANS; CANDIDIASIS; CONFERENCE PAPER; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; HUMAN; IN VITRO STUDY; ISOTOPE LABELING; KLEBSIELLA PNEUMONIAE; MEDIASTINITIS; MYCOSIS; NONHUMAN; RADIOACTIVITY; SCINTIGRAPHY; STAPHYLOCOCCUS AUREUS;

ANIMALS; ANTIFUNGAL AGENTS; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; CANDIDA ALBICANS; CANDIDIASIS; CHITIN; DIAGNOSIS, DIFFERENTIAL; FLUCONAZOLE; HUMANS; LACTOFERRIN; MICE; PEPTIDE FRAGMENTS; RADIOACTIVE TRACERS; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY; TECHNETIUM;

ASPERGILLUS FUMIGATUS; BACTERIA (MICROORGANISMS); CANDIDA ALBICANS; MUS;

EID: 79952680394     PISSN: 13693786     EISSN: 14602709     Source Type: Journal    
DOI: 10.3109/13693786.2010.508188     Document Type: Conference Paper

References (61)

1. Pennisi M, Antonelli M. Clinical aspects of invasive candidiasis in critically ill patients. Drugs 2009; 69(Suppl. 1): 21-28.
2. Pappas PG, Kauffman CA, Andes D, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 48: 503-535.
3. Shoham S, Marwaha S. Invasive fungal infections in the ICU. J Intens Care Med 2010; 25: 78-92.
4. Zilberberg MD, Shorr AF. Fungal infections in the ICU. Infect Dis Clin North Am 2009; 23: 625-642.
5. Koh AY, Köhler JR, Coggshall KT, Van Rooijen N, Pier GB. Mucosal damage and neutropenia are required for Candida albicans dissemination. PLoS Pathog 2008; 4: e35.
6. Dalle F, Wächtler B, L'Ollivier C, et al. Cellular interactions of candida albicans with human oral epithelial cells and enterocytes. Cell Microbiol 2010; 12: 248-271.
7. Pemán J, Zaragoza R. Current diagnostic approaches to invasive can-didiasis in critical care settings. Mycoses 2009. [Epub ahead of print]
8. Wheat LJ. Approach to the diagnosis of invasive aspergillosis and candidiasis. Clin Chest Med 2009; 30: 367-377.
9. 18F-f uoro-2-deoxy-D-glucose (FDG-PET) images of pulmonary cryptococcosis mimicking lung cancer. Eur J Cardiothorac Surg 2006; 30: 837-839. (Pubitemid 44738620)
10. Lupetti A, Welling MM, Pauwels EKJ, Nibbering PH. Radiolabelled antimicrobial peptides for infection detection. Lancet Infect Dis 2003; 3: 223-229. (Pubitemid 36389185)
11. Okarvi SM. Peptide-based radiopharmaceuticals: future tools for diagnostic imaging of cancers and other diseases. Med Res Rev 2004; 24: 357-397. (Pubitemid 38495786)
12. Becker W, Meller J. The role of nuclear medicine in infection and inflammation. Lancet Infect Dis 2001; 1: 326-333. (Pubitemid 33586613)
13. Kumar V. Radiolabeled white blood cells and direct targeting of micro-organisms for infection imaging. Q J Nucl Med Mol Imaging 2005; 49: 325-338. (Pubitemid 43246282)
14. Palestro CJ. In vivo leukocyte labeling: the quest continues. J Nucl Med 2007; 48: 332-334. (Pubitemid 47604912)
15. Zasloff M. Antimicrobial peptides of multicellular organisms. Nature 2002; 415: 389-395. (Pubitemid 34100944)
16. Hancock RE, Sahl HG. Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies. Nat Biotechnol 2006; 24: 1551-1557. (Pubitemid 44967479)
17. Nizet V, Ohtake T, Lauth X, et al. Innate antimicrobial peptide protects the skin from invasive bacterial infection. Nature 2001; 414: 454-457. (Pubitemid 34173727)
18. Dürr UH, Sudheendra US, Ramamoorthy A. LL-37, the only human member of the cathelicidin family of antimicrobial peptides. Biochim Biophys Acta 2006; 1758: 1408-1425.
19. Overhage J, Campisano A, Bains M, et al. Human host defense pep-tide LL-37 prevents bacterial biof lm formation. Infect Immun 2008; 76: 4176-4182.
20. Bergman P, Walter-Jallow L, Broliden K, Agerberth B, Söderlund J. The antimicrobial peptide LL-37 inhibits HIV-1 replication. Curr HIV Res 2007; 5: 410-415. (Pubitemid 47040482)
21. L ó pez-García B, Lee PH, Yamasaki K, Gallo RL. Anti-fungal activity of cathelicidins and their potential role in Candida albicans skin infection. J Invest Dermatol 2005; 125: 108-115. (Pubitemid 40981431)
22. Brouwer CP, Bogaards SJ, Wulferink M, Velders MP, Welling MM. Synthetic peptides derived from human antimicrobial peptide ubiquicidin accumulate at sites of infections and eradicate (multi-drug resistant) Staphylococcus aureus in mice. Peptides 2006; 27: 2585-2591. (Pubitemid 44584404)
23. Nibbering PH, Ravensbergen E, Welling MM, et al. Human lactoferrin and peptides derived from its N terminus are highly effective against infections with antibiotic-resistant bacteria. Infect Immun 2001; 69: 1469-1476. (Pubitemid 32187596)
24. Lupetti A, Paulusma-Annema A, Welling MM, et al. Candidacidal activities of human lactoferrin peptides derived from the N terminus. Antimicrob Agents Chemother 2000; 44: 3257-3263. (Pubitemid 33009481)
25. Lupetti A, van Dissel JT, Brouwer CPJM, Nibbering PH. Human antimicrobial peptides'antifungal activity against Aspergillus fumigatus. Eur J Clin Microbiol Infect Dis 2008; 27: 1125-1129.
26. Lupetti A, Brouwer CPJM, Bogaards SJP, et al. Human lactoferrin-derived peptide's antifungal activities against disseminated Candida albicans infection. J Infect Dis 2007; 196: 1416-1424. (Pubitemid 351412016)
27. Ciornei CD, Sigurdardóttir T, Schmidtchen A, Bodelsson M. Antimicrobial and chemoattractant activity, lipopolysaccharide neutralization, cytotoxicity, and inhibition by serum of analogs of human cathelicidin LL-37. Antimicrob Agents Chemother 2005; 49: 2845-2850. (Pubitemid 40917601)
28. Hiemstra PS, Fernie-King BA, McMichael J, Lachmann PJ, Sallenave JM. Antimicrobial peptides: mediators of innate immunity as templates for the development of novel anti-infective and immune therapeutics. Curr Pharm Des 2004; 10: 2891-2905. (Pubitemid 39172069)
29. De Yang, Chen Q, Schmidt AP, et al. LL-37, the neutrophil granule- and epithelial cell-derived cathelicidin, utilizes formyl peptide receptor-like 1 (FPRL1) as a receptor to chemoattract human peripheral blood neutrophils, monocytes, and T cells. J Exp Med 2000; 192: 1069-1074.
30. Coffelt SB, Marini FC, Watson K, et al. The pro-inflammatory pep-tide LL-37 promotes ovarian tumor progression through recruitment of multipotent mesenchymal stromal cells. Proc Natl Acad Sci USA 2009; 106: 3806-3811.
31. Yuk JM, Shin DM, Lee HM, et al. Vitamin D3 induces autophagy in human monocytes/macrophages via cathelicidin. Cell Host Microbe 2009; 6: 231-243.
32. van der Does AM, Beekhuizen H, Ravensbergen B, et al. Does LL-37 directs macrophage differentiation toward macrophages with a proin-f ammatory signature. J Immunol 2010; 185: 1442-1449.
33. Davidson DJ, Currie AJ, Reid GS, et al. The cationic antimicrobial peptide LL-37 modulates dendritic cell differentiation and dendritic cell-induced T cell polarization. J Immunol 2004; 172: 1146-1156. (Pubitemid 38113775)
34. Mookherjee N, Hancock RE. Cationic host defence peptides: innate immune regulatory peptides as a novel approach for treating infections. Cell Mol Life Sci 2007; 64: 922-933. (Pubitemid 46597762)
35. Piers KL, Brown MH, Hancock RE. Recombinant DNA procedures for producing small antimicrobial cationic peptides in bacteria. Gene 1993; 134: 7-13.
36. Rao AG, Rood T, Maddox J, Duvick J. Synthesis and characterization of defensin NP-1. Int J Pept Protein Res 1992; 40: 507-514. (Pubitemid 23005768)
37. Aumelas A, Mangoni M, Roumestand C, et al. Synthesis and solution structure of the antimicrobial peptide protegrin-1. Eur J Biochem 1996; 237: 575-583. (Pubitemid 26164589)
38. Bellamy W, Takase M, Yamauchi K, et al. Identification of the bactericidal domain of lactoferrin. Biochim Biophys Acta 1992; 1121: 130-136.
39. Hiemstra PS, van den Barselaar MT, Roest M, Nibbering PH, van Furth R. Ubiquicidin, a novel murine microbicidal protein present in the cytosolic fraction of macrophages. J Leukoc Biol 1999; 66: 423-428. (Pubitemid 29439249)
40. van Berkel PHC, Welling MM, Geerts M, et al. Large scale production of recombinant human lactoferrin in the milk of transgenic cows. Nat Biotechnol 2002; 20: 484-487. (Pubitemid 34495935)
41. 99m Tc-UBI 29-41 for imaging of bacterial infections. Nucl Med Biol 2002; 29: 413-422. (Pubitemid 34597113)
42. 99m Tc-labeled human neutrophil peptide-1. J Nucl Med 1999; 40: 2073-2080. (Pubitemid 30022024)
43. Kenna S, Bligh HF, Watson PF, Kelly SL. Genetic and physiological analysis of azole sensitivity in Saccharomyces cerevisiae. J Med Vet Mycol 1989; 27: 397-406. (Pubitemid 20131646)
44. Aguilar PS, Heiman MG, Walther TC, et al. Structure of sterol aliphatic chains affects yeast cell shape and cell fusion during mating. Proc Natl Acad Sci USA 2010; 107: 4170-4175.
45. Blok D, Feitsma RI, Vermeij P, Pauwels EKJ. Peptide radiopharma-ceuticals in nuclear medicine. Eur J Nucl Med 1999; 26: 1511-1519.
46. 99m Tc-Infecton, a novel agent for detecting sites of infection. J Clin Pathol 1998; 51: 215-219. (Pubitemid 28216078)
47. Lupetti A, Welling MM, Mazzi U, Nibbering PH, Pauwels EKJ. Technetium-99m labelled fluconazole and antimicrobial peptides for imaging of candida albicans and Aspergillus fumigatus infections. Eur J Nucl MedMol Imaging 2002; 29: 674-679. (Pubitemid 34439329)
48. 4 and stannous chloride. Nucl Med Biol 1993; 20: 825-833. (Pubitemid 23278227)
49. Welling MM, Paulusma-Annema A, Balter HS, Pauwels EKJ, Nibbering PH. Technetium-99m labelled antimicrobial peptides discriminate between bacterial infections and sterile inflammations. Eur J Nucl Med 2000; 27: 292-301. (Pubitemid 30167699)
50. 99mTc-labeled antimicrobial peptides for detection of bacterial and Candida albicans infections. J Nucl Med 2001; 42: 788-794. (Pubitemid 32453471)
51. Lupetti A, Welling MM, Pauwels EKJ, Nibbering PH. Detection of fungal infections using radiolabeled antifungal agents. Curr Drug Targets 2005; 6: 945-954. (Pubitemid 41672454)
52. 18F-labeled fluconazole in rabbits with candidal infections studied with positron emission tomography. J Pharmacol Exp Ther 1991; 259: 1351-1359.
53. Welling MM, Visentin R, Lupetti A, et al. Radiochemical and biological characteristics of Technetium-99m labelled fluconazole. In: M. Nicolini and U. Mazzi (eds), Technetium, Rhenium and Other Metals in Chemistry and Nuclear Medicine. Padova: SGE Editoriali, 2002, 655-659. ISBN 88-86281-73-0.
54. 99m Tc-UBI 29-41 in humans. Nucl Med Biol 2004; 31: 373-379. (Pubitemid 38353033)
55. 99m Tc-ubiquicidin 29-41 as human infection-imaging agent: clinical trial. J Nucl Med 2005; 46: 567-573. (Pubitemid 41716399)
56. 99mTc-labeled ubiquicidin 29-41 antimicrobial peptide for the scintigraphic detection of mediastinitis after cardiac surgery. Arch Med Res 2008; 39: 768-774.
57. 123 I-labeled chitinase as specific radioligand for in vivo detection of fungal infections in mice. J Nucl Med 2004; 45: 1209-1216. (Pubitemid 47611667)
58. 99m Technetium labeled chitin-binding protein as potential specific radioligand for the detection of fungal infections in mice. Q J Nucl Med Mol Imaging 2006; 50: 155-166. (Pubitemid 44649657)
59. Guan Y, Chye ML. A Brassica juncea chitinase with two-chitin binding domains show anti-microbial properties against phyto-pathogens and gram-negative bacteria. Plant Signal Behav 2008; 3: 1103-1105. (Pubitemid 352847672)
60. Zhu Z, Zheng T, Homer RJ, et al. Acidic mammalian chitinase in asthmatic Th2 inflammation and IL-13 pathway activation. Science 2004; 304: 1678-1682. (Pubitemid 38765861)
61. Ober C, Tan Z, Sun Y, et al. Effect of variation in CHI3L1 on serum YKL-40 level, risk of asthma, and lung function. N Engl J Med 2008; 358: 1682-1691. (Pubitemid 351549915)